All In Biotech

Drug Trial Radar · NCT00358176

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 Months.

Last checked: Nov 20, 2026Latest source record: Dec 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,231

Actual

Start

Jul 2004

Primary completion

Mar 2007

Study completion Mar 2007

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Procter and Gamble
First posted
Jul 31, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar spine in postmenopausal women with osteoporosis. To confirm the efficacy of 75 mg risedronate tablets taken on 2 consecutive days per month in postmenopausal women with osteoporosis in increasing bone mass in proximal femur, femoral neck and femoral trochanter and decreasing bone resorption. To confirm general safety of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate taken daily.

Conditions

  • Osteoporosis Postmenopausal

Interventions

  • Risedronate (HMR4003)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in lumbar spine bone mineral density (BMD) at
  2. Month 12 measured by dual-energy X-ray absorptiometry (DXA).

Locations

11 sites in 11 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Bridgewater, New Jersey

  • Sanofi-Aventis

    San Isidro, Argentina

  • Sanofi-Aventis

    Macquarie Park, Australia

  • Sanofi-Aventis

    Laval, Canada

  • Sanofi-Aventis

    Prague, Czechia

  • Sanofi-Aventis

    Paris, France

  • Sanofi-Aventis

    Beirut, Lebanon

  • Sanofi-Aventis

    Warsaw, Poland

  • Sanofi-Aventis

    Midrand, South Africa

  • Sanofi-Aventis

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis

    Guildford Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.